Papilledema Due to Immune Checkpoint Inhibitor-Associated Subdural Effusions
- PMID: 38715193
- DOI: 10.1097/WNO.0000000000002160
Papilledema Due to Immune Checkpoint Inhibitor-Associated Subdural Effusions
Conflict of interest statement
The authors report no conflicts of interest.
References
-
- Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint inhibitor immune therapy. Retina. 2018;38:1063–1078.
-
- Marini A, Bernardini A, Gigli GL, et al. Neurologic adverse events of immune checkpoint inhibitors. Neurology. 2021;96:754–766.
-
- Roth P, Winklhofer S, Müller AMS, et al. Neurological complications of cancer immunotherapy. Cancer Treat Rev. 2021;97:102189.
-
- Sun MM, Seleme N, Chen JJ, et al. Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1/PD-L1 checkpoint blockade. J Neuro-Ophthalmology. 2021;41:519–530.
-
- Zhou YW, Wang Y, Xia RL, Liu JY, Ma XL. Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management. Int J Ophthalmol. 2022;15:646–656.
LinkOut - more resources
Full Text Sources